The chief scientific officer at Athira talked about the potential of hepatocyte growth factor compounds in promoting neurotrophic signaling and providing broad neuroprotection across neurodegenerative diseases. [WATCH TIME: 6 minutes]
The professor of neurology at Johns Hopkins University School of Medicine talked about the need for education to optimize treatment selection and the continually changing landscape of care for patients with epilepsy. [WATCH TIME: 5 minutes]
The consultant in the Department of Neurology at Mayo Clinic discussed the mechanisms of action researchers should key in on for patients with Parkinson disease.
Mary Anne Meskis; Tracy Dixon-Salazar, PhD; Kelly Knupp, MD; and Joseph E. Sullivan, MD, provide advice for physicians treating patients with Dravet syndrome or LGS.
The vascular neurologist at Cleveland Clinic provided an overview of a study that assessed the extent HbA1c impacts the relationship between mechanical thrombectomy and poor outcomes. [WATCH TIME: 3 minutes]
The clinical director of the National Institute of Neurological Disorders and Stroke provided context on two recent papers that highlight a reactivation of HERV-K virus in the development of amyotrophic lateral sclerosis. [WATCH TIME: 5 minutes]
A group of experts from The Neuron Clinic shared their experience developing a novel inclusive clinical program to treat patients with early Alzheimer disease using lecanemab.
The health research assistant at the Shepherd Center discussed the importance of interventions that address mental health for patients with multiple sclerosis, including counseling and support groups. [WATCH TIME: 2 minutes]
The chair of the Department of Neurology and the director of the Neuroscience Research Institute at The Ohio State University discussed the takeaways from his lecture at ACTRIMS Forum 2021.
The director of the Multiple Sclerosis and Neuromyelitis Optica Unit at Massachusetts General Hospital commented on presentations given at the recent event, as well as key takeaways from his own discussion on novel imaging approaches in multiple sclerosis. [WATCH TIME: 2 minutes]
Glenn Graham, MD, PhD; and Sharyl Martini, MD, PhD, moderate a discussion with 4 clincial experts to advance specialized clinical care, education and research for Veterans with movement disorders, multiple sclerosis, epilepsy and seizures, and headache. [WATCH TIME: 1 hour, 52 minutes]
The director of the Muscular Dystrophy Clinic at UCSF Benioff Children’s Hospital provided insight on promising data from the phase 2/3 VIBRANCE-MG study assessing investigational nipocalimab in adolesents with myasthenia gravis. [WATCH TIME: 3 minutes]
The professor of neurology at Emory University School of Medicine spoke on the potential for the new AASM hypersomnolence guideline to educate providers treating patients with sleep disorders.
The head of CRCSEP and coordinator of the Neurosciences Research Unit at Paris City University discussed the positive results of teriflunomide in treating radiologically isolated syndrome, a preclinical stage of multiple sclerosis. [WATCH TIME: 4 minutes]
Panelists discuss how in multiple sclerosis (MS) treatment, clinicians must strategically evaluate disease progression, considering within-class or mechanism-of-action switches. Comprehensive monitoring, personalized approaches, and proactive management are crucial for optimizing patient outcomes and minimizing long-term neurological disability.
The assistant professor of neurology at Wake Forest School of Medicine provided clinical insight on MG0020, a phase 3 trial assessing a self-administration of rozanolixizumab through a syringe driver. [WATCH TIME: 3 minu]
The director of the neurological disease center at Beijing Anzhen Hospital talked about assessing the potential benefits and safety of intra-arterial tenecteplase in highly selected poststroke patients. [WATCH TIME: 6 minutes]
The director of the Center for Biologics Evaluation Research at the FDA provided an overview of the Keynote Address he gave at the 2023 Muscular Dystrophy Association Clinical and Scientific Conference. [WATCH TIME: 3 minutes]
The senior investigator in the Neuromuscular and Neurogenetic Disorders of Childhood Section at NINDS shared his perspective on the data coming out of neuromuscular research and the promise of genetic medicine. [WATCH TIME: 2 minutes]
A pilot study, presented at the 2025 AD/PD conference, evaluating the CUE1 device suggests it may help improve motor symptoms and reduce fall risk in patients with Parkinson disease.
The neuromuscular and movement disorders speech-language pathologist at Orlando Health discussed strategies in managing the phases of multiple sclerosis for patients and the need for collaborative referral practices. [WATCH TIME: 5 minutes]
Neurology experts discuss the unmet needs in narcolepsy treatment and share clinical pearls from their experiences.
When asked about developments, the neurologist and movement disorders specialist at Sheba Tel-HaShomer Medical Center in Israel commented on the need to identify disease-modifying therapies. [WATCH TIME: 3 minutes]
The assistant professor of neurology at Massachusetts General Hospital and Harvard Medical School spoke about the high risk of epilepsy for the older population at the 2022 AES annual meeting. [WATCH TIME: 1 minute]
The field of Alzheimer disease has entered a new era of earlier detection, creating an opportunity to redefine treatment and the clinical care of patients.
Although combination carbidopa-levodopa has become a standard for the treatment of many of the motor features of PD to this day, gait dysfunction remains a difficult symptom to treat.
The assistant professor of occupational therapy at the New York Institute of Technology talked about educating patients with Parkinson disease about the importance of maintaining social participation for cognitive function at ATMRD 2023. [WATCH TIME: 5 minutes]
Excessive daytime sleepiness is a hallmark of a number of sleep disorders, and ensuring the proper diagnosis and management of those presenting with it is crucial to care.